Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adecoagro SA (AGRO) vs Moderna, Inc. (MRNA) Price & Performance

Adecoagro SATrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Adecoagro SA vs Moderna, Inc. — how do they compare? Adecoagro SA trades at $9.24 (market cap $1.36B), while Moderna, Inc. trades at $63.7 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 17.8× Adecoagro SA's market cap, and Adecoagro SA pays a 3.15% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

AGROMRNA
Market Cap
$1.36B$24.18B
Sector
TechnologyHealth
52-Week High
$15.25$81.80
52-Week Low
$7.13$22.36
Enterprise Value
$3.39B$20.33B
Dividend Yield
3.15%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adecoagro SA

AGRO trades at $9.29, down 3.83% today, with a bearish technical signal and mixed earnings performance. The company reported strong adjusted EBITDA growth in Q2 2026 ($172.5M) and is expanding via acquisition of the Caarapó mill. However, recent quarters show earnings misses against expectations, with net income margin at just 0.91% for 2026. Valuation metrics appear reasonable with P/S of 0.71 and P/B of 0.77, but high P/E of 522.78 reflects profitability challenges.

The outlook remains cautious with analyst consensus leaning toward Hold (50%) amid execution risks from recent acquisitions and commodity volatility. Positive catalysts include operational efficiency gains and expansion in South American markets, but investors face headwinds from elevated leverage and macroeconomic sensitivity to oil and gas prices.

Moderna, Inc.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

Returns comparison

Trailing returns across standard periods

About Adecoagro SA

Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.

Read more on AGRO

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA